Further functional assays demonstrating activity of LRH-1-specific T cells against multiple LRH-1 genetically positive leukemia cell targets in vitro, and ideally in patient-derived murine xenograft models, are required before translation of LRH-1-specific T cell immunotherapy to the clinic. This evidence concerns the gene P2RX5 and leukemia.